Abstract
Over the last decade, antibodies have become an important component in the arsenal of cancer therapeutics. High-specificity, low off-target effects, desirable pharmacokinetics and high success rate are a few of the many attributes that make antibodies amenable for development as drugs. To design antibodies for successful clinical applications, however, it is critical to have an understanding of their structure, functions, mechanisms of action and pharmacokinetic/pharmacodynamic properties. This review highlights some of these key aspects, as well as certain limitations encountered, with monoclonal antibody therapy. Further, we discuss rational combination therapies for clinical applications, some of which could help overcome the limitations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 255-267 |
| Number of pages | 13 |
| Journal | Immunotherapy |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Mar 2020 |
Bibliographical note
Publisher Copyright:© 2020 Future Medicine Ltd.
Keywords
- cancer
- combinations
- mechanisms
- monoclonal antibodies
- structure
